MRI Seems Safe for Patients With Legacy Pacemaker, ICD SystemLast Updated: December 27, 2017. For patients with a legacy pacemaker or implantable cardioverter-defibrillator system, magnetic resonance imaging conducted at a strength of 1.5 Tesla is safe, according to a study published in the Dec. 28 issue of the New England Journal of Medicine.
WEDNESDAY, Dec. 27, 2018 (HealthDay News) -- For patients with a legacy pacemaker or implantable cardioverter-defibrillator system, magnetic resonance imaging (MRI) conducted at a strength of 1.5 Tesla is safe, according to a study published in the Dec. 28 issue of the New England Journal of Medicine.
Saman Nazarian, M.D., Ph.D., from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues conducted a prospective, nonrandomized trial to examine the safety of MRI at a magnetic field strength of 1.5 Tesla in 1,509 patients with a pacemaker or an implantable cardioverter-defibrillator (58 and 42 percent, respectively) that was not considered to be MRI-conditional (a legacy device). The patients underwent 2,103 clinically necessary thoracic and nonthoracic MRI examinations. For pacing-dependent patients, the pacing mode was changed to asynchronous mode, while for others it was changed to demand mode.
The researchers found that there were no reports of long-term clinically significant adverse events. The patient's device reset to a backup mode in nine MRI examinations (0.4 percent); in eight of them, the reset was transient. One pacemaker with less than one month left of battery life reset to ventricular inhibited pacing and could not be reprogrammed. A decrease in P-wave amplitude was the most common notable change in device parameters (occurred in 1 percent of patients) immediately after MRI. At long-term follow-up, the most common notable changes from baseline were decreases in P-wave amplitude, increases in atrial capture threshold, increases in right ventricular capture threshold, and increases in left ventricular capture threshold (4, 4, 4, and 3 percent, respectively).
"The observed changes in lead parameters were not clinically significant and did not require device revision or reprogramming," the authors write.
Several authors disclosed financial ties to the medical device industry.
|Previous: Ob-Gyns Encouraged to Consider Social Determinants of Health||Next: Variation Seen in Hospice Use for Malignant Glioma|
Reader comments on this article are listed below. Review our comments policy.